廣濟藥業(000952.SZ)上半年淨利預增163.90%-243.07%
格隆匯7月13日丨廣濟藥業(000952.SZ)披露2021年半年度業績預吿,預計2021年1-6月實現歸屬於上市公司股東的淨利潤5000萬元-6500萬元,同比增長163.90%-243.07%;預計2021年1-6月實現歸屬於上市公司股東的扣除非經常性損益的淨利潤2800萬元-3600萬元,同比增長53.79%-97.73%。業績預增的主要原因系:
1、報吿期內公司醫藥級VB2、VB6產品銷量增加;
2、報吿期內公司正常生產,而2020年同期受新型冠狀病毒肺炎疫情影響公司被動停工,公司停工損失同比大幅度下降;
3、報吿期內公司銀行借款餘額減少導致利息支出同比下降;
4、報吿期內公司預計非經常性損益對歸屬於上市公司股東的淨利潤的影響約2600萬元,主要原因為公司聯營單位湖北安華大廈有限公司在該年度進行債權債務清理及與債權單位進行了債務重組所形成的利得。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.